Quince Therapeutics, Inc.
QNCX
$0.9905
-$0.0095-0.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -50.85% | -22.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.96% | -3.35% | |||
| Operating Income | 10.96% | 3.35% | |||
| Income Before Tax | -127.25% | 80.22% | |||
| Income Tax Expenses | -46.15% | -63.89% | |||
| Earnings from Continuing Operations | -126.84% | 80.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -126.84% | 80.19% | |||
| EBIT | 10.96% | 3.35% | |||
| EBITDA | 10.25% | 3.84% | |||
| EPS Basic | -123.74% | 80.23% | |||
| Normalized Basic EPS | 2.79% | 2.31% | |||
| EPS Diluted | -123.74% | 80.23% | |||
| Normalized Diluted EPS | 2.79% | 2.31% | |||
| Average Basic Shares Outstanding | 1.42% | 0.16% | |||
| Average Diluted Shares Outstanding | 1.42% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||